Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimensGuan‐Jhou Chen, Chien‐Ching Hung, Kuan‐Yin Lin et al.|International Journal of Antimicrobial Agents|2022Cited by 25
Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIVKuan‐Yin Lin, Hsin‐Yun Sun, Chia‐Jui Yang et al.|Clinical Infectious Diseases|2023Cited by 12
Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir/emtricitabine/tenofovir alafenamideJen‐Yu Hsu, Chien‐Ching Hung, Hsin‐Yun Sun et al.|Journal of Global Antimicrobial Resistance|2023Cited by 10
Short-term evolution of Mpox-specific IgG and neutralizing antibodies among individuals undergoing MVA-BN vaccinationWang-Da Liu, Chien‐Ching Hung, Tai‐Ling Chao et al.|International Journal of Infectious Diseases|2025Cited by 8
Evolution of anti-SARS-CoV-2 spike protein titers after two-dose of COVID-19 vaccination among people living with HIVWang-Da Liu, Man Wai Pang, Jann‐Tay Wang et al.|Journal of Virus Eradication|2022Cited by 6